Regulatory glossary

Biologics License Application (BLA): What It Is and How to File One

A Biologics License Application is the submission a sponsor files to get permission to market a biological product in the United States. It is filed under section 351 of the Public Health Service Act, and the procedures live in 21 CFR Part 601.

Where a small-molecule drug is approved through an NDA, a biologic is licensed through a BLA. The distinction is not cosmetic: the application licenses both the product and the establishment that makes it, which is why manufacturing carries so much more weight in a BLA review than most first-time sponsors expect.

BLA vs NDA vs ANDA

A biosimilar is filed as a 351(k) application, a distinct pathway that demonstrates similarity to an already-licensed reference product rather than establishing safety and effectiveness from scratch.

Who reviews your BLA

This trips people up, because "biologic" does not map cleanly onto one center. Under the CBER/CDER intercenter agreement:

• CBER reviews vaccines, blood and blood products, allergenic products, cell therapies and gene therapies.
• CDER reviews most therapeutic proteins, including monoclonal antibodies, cytokines, growth factors, enzymes and immunomodulators.

So a monoclonal antibody goes to CDER even though it is unambiguously a biologic. Confirming your review division early matters, because it determines who you meet with, which guidances bind you, and what the review culture expects of your dossier.

What goes into a BLA

The application is submitted on Form FDA 356h in eCTD format. The CTD modules carry the substance:

• Module 1 — regional administrative information: the form, cover letter, proposed labeling, patent and exclusivity statements, REMS if applicable.
• Module 2 — the summaries. The Quality Overall Summary, the Nonclinical and Clinical Overviews, and the written and tabulated summaries including the Clinical Summary sections.
• Module 3 — Quality. For a biologic this is the heart of the application: drug substance and drug product manufacture, characterisation, control of materials, process validation, comparability across process changes, stability.
• Module 4 — nonclinical study reports.
• Module 5 — clinical study reports, including the pivotal trial CSRs, ISS and ISE.

The establishment itself is part of what gets licensed, so the facility information and the pre-licence inspection are not administrative afterthoughts. They are a common reason applications do not get approved on the first cycle.

Review timelines

Under the PDUFA VII commitments, FDA's review goals are:

• Standard review — 10 months from the 60-day filing date.
• Priority review — 6 months from the 60-day filing date.

Add the 60-day filing period and a standard review runs roughly 12 months from submission. Expedited programmes (Fast Track, Breakthrough Therapy, Accelerated Approval, RMAT for regenerative medicine) change the interaction model and sometimes the evidence standard, but priority review is what changes the clock.

What happens if FDA does not approve it

You receive a Complete Response Letter listing every deficiency. The application stays open, and you may resubmit, withdraw, or request a hearing.

FDA now publishes CRLs through openFDA. Of the 445 Complete Response Letters in the published corpus, 103 (23%) were issued against BLAs and 328 against NDAs. Reading the ones issued in your own therapeutic area is the cheapest available preparation for a BLA review, because they tell you in the agency's own words what a review division found insufficient.

Across published CRLs generally, manufacturing and facility problems are cited far more often than clinical failure. For a BLA, where the licence covers the establishment, that skew is the single most useful thing to know going in.

Common reasons a first BLA goes badly

• Comparability gaps after a process change. Almost every programme changes its process between early clinical and commercial scale. If the comparability package does not bridge the material used in the pivotal trial to the material you intend to sell, the clinical data does not transfer cleanly.
• The facility is not ready when the application is. The pre-licence inspection is scheduled against your submission, not against your readiness.
• Contract manufacturers. You are accountable for a site you do not run. Their inspection history becomes your approvability issue.
• Specifications that are not justified. Setting an acceptance criterion is easy; defending it against the batch and stability data is where reviews stall.
• Module 2 summaries that do not match Module 3. Reviewers read the summary and check the source. Any number that disagrees becomes an information request.